Citations

Clear

959 citation(s) found for "Service, F J".

The Movement Disorder Society Criteria for the Diagnosis of Multiple System Atrophy
Stanković, Iva , Vignatelli, Luca , Fanciulli, Alessandra , Calandra–Buonaura, Giovanna , Seppi, Klaus , Palma, Jose‐Alberto , Meissner, Wassilios G. , Krismer, Florian , Berg, Daniela , Halliday, Glenda M. , Ling, Helen , Low, Phillip A. , Panicker, Jalesh N. , Pellecchia, Maria Teresa , Quinn, Niall , Stamelou, María , Tolosa, Eduardo , Warner, Tom, Stankovic, Iva , Vignatelli, Luca , Fanciulli, Alessandra , Seppi, Klaus , Palma, Jose-Alberto , Meissner, Wassilios G , Krismer, Florian , Cortelli, Pietro , Halliday, Glenda , Höglinger, Günter U , Ling, Helen , Sakakibara, Ryuji , Stamelou, Maria , Kaufmann, Horacio , Pellecchia, Maria Teresa , Wenning, Gregor K. , Cortelli, Pietro , Freeman, Roy L. , Höglinger, Günter U. , Lang, Anthony E. , Litvan, Irene , Miki, Yasuo , Sakakibara, Ryuji , Tsuji, Shoji , Warner, Tom, Poewe, Werner H

Mayo Clinic

Movement Disorders | April 21, 2022 | Volume: 37 | Issue: 6 | Pages: 1131-1148

10.1002/mds.29005 | PMID 35445419 Get It

ABSTRACT Background The second consensus criteria for the diagnosis of multiple system atrophy (MSA) are widely recognized as the reference standard for clinical research, but lack sensitivity to diagnose the disease at early stages. Objective To develop novel Movement Disorder Society (MDS) criteria for MSA diagnosis using an evidence‐based and consensus‐based methodology. Methods We identified shortcomings of the second consensus criteria for MSA diagnosis and conducted a systematic literature review to answer predefined questions on clinical presentation and diagnostic tools relevant for MSA diagnosis. The criteria were developed and later optimized using two Delphi rounds within the MSA Criteria Revision Task Force, a survey for MDS membership, and a virtual Consensus Conference. Results The criteria for neuropathologically established MSA remain unchanged. For a clinical MSA diagnosis a new category of clinically established MSA is introduced, aiming for maximum specificity with acceptable sensitivity. A category of clinically probable MSA is defined to enhance sensitivity while maintaining specificity. A research category of possible prodromal MSA is designed to capture patients in the earliest stages when symptoms and signs are present, but do not meet the threshold for clinically established or clinically probable MSA. Brain magnetic resonance imaging markers suggestive of MSA are required for the diagnosis of clinically established MSA. The number of research biomarkers that support all clinical diagnostic categories will likely grow. Conclusions This set of MDS MSA diagnostic criteria aims at improving the diagnostic accuracy, particularly in early disease stages. It requires validation in a prospective clinical and a clinicopathological study. © 2022 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society
Zanubrutinib monotherapy in relapsed/refractory indolent non-Hodgkin lymphoma
Chan, Henry , Tam, Constantine S. , Tedeschi, Alessandra , Johnston, Patrick B. , Opat, Stephen , Eom, Hyeon‐Seok , Allewelt, Heather, Tan, Ziwen , Novotny, William , Huang, Jane , Chan, Henry , Tam, Constantine S , Opat, Stephen , Eom, Hyeon-Seok , Trotman, Judith , Phillips, Tycel , Oh, Sung Yong , Stern, Jennifer C.

Mayo Clinic

Blood Advances | April 7, 2022 | Volume: 6 | Issue: 11 | Pages: 3472-3479

10.1182/bloodadvances.2021006083 | PMID 35390135 Get It

Abstract Outcomes for marginal zone lymphoma (MZL) and follicular lymphoma (FL) remain suboptimal, owing to the limited number of approved agents and the incurable nature of the diseases. BGB-3111-AU-003 was a phase 1/2, open-label, multicenter, single-agent study of the selective Bruton’s tyrosine kinase inhibitor zanubrutinib in 385 patients with B-cell malignancies. Here, we present safety and efficacy outcomes for the 53 enrolled patients with relapsed/refractory MZL (n = 20) and relapsed/refractory FL (n = 33), all of whom were enrolled during the part 2 dose expansion, and therefore received zanubrutinib at the recommended phase 2 dose. Treatment with zanubrutinib was generally well tolerated, with most adverse events being ≤ grade 2. Atrial fibrillation/flutter was not reported. Two patients required dose reduction, and 4 patients discontinued treatment because of adverse events. Response was assessed by an independent review committee for MZL and the investigators for FL, per Lugano 2014 classification for non-Hodgkin lymphoma. In patients with MZL, the overall response rate (ORR) was 80%, and the complete response (CR) rate was 20%. With median follow-up of 33.8 months, median progression-free survival (PFS) was not reached. In patients with FL, the ORR was 36.4%, and the CR rate was 18.2%. After a median follow-up of 33.9 months, median PFS was 10.4 months. In conclusion, the results of this study suggest a favorable benefit–risk profile and support zanubrutinib as a potentially meaningful addition to available therapies for patients with relapsed/refractory MZL and FL. This trial was registered at www.clinicaltrials.gov as #NCT02343120.
European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) Expert Consensus Statement on the state of genetic testing
Wilde, Arthur A.M. , Semsarian, Christopher, Shamloo, Alireza Sepehri , Ackerman, Michael J. , Ashley, Euan A. , Eduardo, Back Sternick, Barajas-Martínez, Héctor , Behr, Elijah R. , Breckpot, Jeroen , Chockalingam, Priya , Crotti, Lia , Lubitz, Steven A. , Makita, Naomasa , Ohno, Seiko, Ortiz‐Genga, Martín, Sacilotto, Luciana , Schulze‐Bahr, Eric , Sotoodehnia, Nona , Tadros, Rafik, Ware, James S. , Kaufman, Elizabeth S. , Aiba, Takeshi , Bollmann, Andreas, Choi, Jong‐Il , Dalal, Aarti , Darrieux, Francisco , Giudicessi, John, Guerchicoff, Mariana , Intyre, Ciorsti Mac, Mackall, Judith A. , Napolitano, Carlo , Juan, Pablo Ochoa, Peichl, Petr , Pereira, Alexandre C. , Skinner, Jon, Tfelt‐Hansen, Jacob , Deneke, Thomas, Mac Intyre, Ciorsti, Crotti, Lia , Makita, Naomasa , Behr, Elijah Raphael , Tfelt-Hansen, Jacob , Lubitz, Steven A , Peichl, Petr , Ware, James S , Márquez, Manlio F. , Bezzina, Connie R. , Charron, Philippe , Gollob, Michael H. , Ohno, Seiko , Shimizu, Wataru , Winlaw, David Scott , Aiba, Takeshi , Giudicessi, John R. , Hong, Kui , Krahn, Andrew D. , Mont, Lluís , Schwartz, Peter J. , Stellbrink, Christoph , Deneke, Thomas

Mayo Clinic

Journal of Arrhythmia | April 4, 2022 | Volume: 38 | Issue: 4 | Pages: 491-553

10.1002/joa3.12717 | PMID 35936045 Get It

European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) Expert Consensus Statement on the state of genetic testing for cardiac diseases
Wilde, Arthur A.M. , Semsarian, Christopher, Shamloo, Alireza Sepehri , Ackerman, Michael J. , Ashley, Euan A. , Barajas-Martinez, Héctor, Behr, Elijah R. , Breckpot, Jeroen , Chockalingam, Priya, Crotti, Lia , Lubitz, Steven A. , Makita, Naomasa , Ohno, Seiko , Ortiz‐Genga, Martín, Sacilotto, Luciana, Schulze‐Bahr, Eric , Sotoodehnia, Nona , Ware, James S. , Kaufman, Elizabeth S. , Reviewers, Document, Aiba, Takeshi , Bollmann, Andreas, Choi, Jong‐Il , Dalal, Aarti , Darrieux, Francisco , Giudicessi, John, Guerchicoff, Mariana , MacIntyre, Ciorsti, Mackall, Judith A. , Napolitano, Carlo , Ochoa, Juan Pablo , Peichl, Petr , Pereira, Alexandre C., Skinner, Jon, Tfelt‐Hansen, Jacob , Deneke, Thomas, Crotti, Lia , Sacilotto, Luciana , Chockalingam, Priya , Crotti, Lia , Makita, Naomasa , Behr, Elijah Raphael , Tfelt-Hansen, Jacob , Lubitz, Steven A , Peichl, Petr , Ware, James S , Márquez, Manlio F. , Sternick, Eduardo Back , Bezzina, Connie R. , Charron, Philippe , Gollob, Michael H. , Ohno, Seiko , Shimizu, Wataru , Tadros, Rafik , Winlaw, David Scott , Reviewers, Document, Aiba, Takeshi , Giudicessi, John R. , Hong, Kui , Krahn, Andrew D. , Mont, Lluís , Schwartz, Peter J. , Stellbrink, Christoph , Deneke, Thomas

Mayo Clinic

Europace | April 4, 2022 | Volume: 24 | Issue: 8 | Pages: 1307-1367

10.1093/europace/euac030 | PMID 35373836 Get It

Proteome-Wide Response of Dormant Caryopses of the Weed, Avena fatua, After Colonization by a Seed-Decay Isolate of Fusarium avenaceum
Lewis, Ricky W., Okubara, Patricia A. , Sullivan, Tarah S., Madden, Benjamin J., Johnson, Kenneth L., Charlesworth, M. Cristine, Fuerst, E. Patrick , Lewis, Ricky W., Okubara, Patricia A. , Sullivan, Tarah S., Madden, Benjamin J., Johnson, Kenneth L., Charlesworth, M. Cristine, Fuerst, E. Patrick

Mayo Clinic

Phytopathology® | April 2, 2022 | Volume: 112 | Issue: 5 | Pages: 1103-1117

10.1094/phyto-06-21-0234-r | PMID 35365054 Get It

Promoting seed decay is an ecological approach to reducing weed persistence in the soil seedbank. Previous work demonstrated that Fusarium avenaceum F.a.1 decays dormant Avena fatua (wild oat) caryopses and induces several defense enzyme activities in vitro. The objectives of this study were to obtain a global perspective of proteins expressed after F.a.1-caryopsis colonization by conducting proteomic evaluations on (i) leachates, soluble extrinsic (seed-surface) proteins released upon washing caryopses in buffer and (ii) proteins extracted from whole caryopses; interactions with aluminum (Al) were also evaluated in the latter study because soil acidification and associated metal toxicity are growing problems. Of the 119 leachate proteins classified as defense/stress, 80 were induced or repressed. Defense/stress proteins were far more abundant in A. fatua (35%) than in F.a.1 (12%). Avena defense/stress proteins were also the most highly regulated category, with 30% induced and 35% repressed by F.a.1. Antifungal proteins represented 36% of Avena defense proteins and were the most highly regulated, with 36% induced and 37% repressed by F.a.1. These results implicate selective regulation of Avena defense proteins by F.a.1. Fusarium proteins were also highly abundant in the leachates, with 10% related to pathogenicity, 45% of which were associated with host cell wall degradation. In whole caryopsis extracts, fungal colonization generally resulted in induction of a similar set of Avena proteins in the presence and absence of Al. Results advance the hypothesis that seed decay pathogens elicit intricate and dynamic biochemical responses in dormant seeds.
Accessory Genomes Drive Independent Spread of Carbapenem-Resistant Klebsiella pneumoniae Clonal Groups 258 and 307 in Houston, TX
Shropshire, William C. , Dinh, An Q , Earley, Michelle, Komarow, Lauren , Panesso, Diana , Rydell, Kirsten, Gómez-Villegas, Sara I, Miao, Hongyu , Hill, Carol , Chen, Liang , Patel, Robin , Abbo, Lilian M. , Cober, Eric , Revolinski, Sara , Luterbach, Courtney , Chambers, Henry F. , Fowler, Vance G. , Shelburne, Samuel A. , Kreiswirth, Barry N. , Hanson, Blake , Arias, César A. , Revolinski, Sara , Bonomo, Robert A , Shelburne, Samuel A , Kreiswirth, Barry N , van Duin, David , Hanson, Blake M , Chen, Liang , Patel, Robin , Abbo, Lilian M , Fries, Bettina C. , Fowler, Vance G. , Bonomo, Robert A. , Arias, César A.

Mayo Clinic

mBio | March 31, 2022 | Volume: 13 | Issue: 2 | Pages: No page available

10.1128/mbio.00497-22 | PMID 35357213 Get It

The prevalence of carbapenem-resistant Klebsiella pneumoniae (CR Kp ) infections in nosocomial settings remains a public health challenge. High-risk clones such as clonal group 258 (CG258) are particularly concerning due to their association with bla KPC carriage, which can severely complicate antimicrobial treatments.
How do I implement an outpatient program for the administration of convalescent plasma for COVID‐19?
Bloch, Evan M. , Tobian, Aaron A.R. , Gniadek, Thomas J. , Cachay, Edward R. , Kafka, Kimberly, Marshall, Christi E., Heath, Sonya L. , Forthal, Donald N. , Fukuta, Yuriko , Huamán, Moisés A. , Ziman, Alyssa , Adamski, Jill , Gerber, Jonathan M. , Cruser, Daniel, Patel, Bela , Metcalf, Ryan A. , Reisler, Ronald B. , Yarava, Anusha , Lane, Karen , McBee, Nichol , Gawad, Amy L., Abinante, Matthew, Broderick, Patrick , Sullivan, David , Ziman, Alyssa , Adamksi, Jill , Raval, Jay S , Metcalf, Ryan A , Tobian, Aaron A R , Huaman, Moises A , Sullivan, David J , Shoham, Shmuel , Hanley, Daniel F. , Meisenberg, Barry R. , Shenoy, Aarthi , Paxton, James H , Levine, Adam C , Kassaye, Seble , Mosnaim, Giselle S , Anjan, Shweta , Raval, Jay S. , Zand, Martin S. , Broderick, Patrick B., Casadevall, Arturo , Gebo, Kelly A

Mayo Clinic

Transfusion | March 30, 2022 | Volume: 62 | Issue: 5 | Pages: 933-941

10.1111/trf.16871 | PMID 35352362 Get It

AbstractConvalescent plasma, collected from donors who have recovered from a pathogen of interest, has been used to treat infectious diseases, particularly in times of outbreak, when alternative therapies were unavailable. The COVID‐19 pandemic revived interest in the use of convalescent plasma. Large observational studies and clinical trials that were executed during the pandemic provided insight into how to use convalescent plasma, whereby high levels of antibodies against the pathogen of interest and administration early within the time course of the disease are critical for optimal therapeutic effect. Several studies have shown outpatient administration of COVID‐19 convalescent plasma (CCP) to be both safe and effective, preventing clinical progression in patients when administered within the first week of COVID‐19. The United States Food and Drug Administration expanded its emergency use authorization (EUA) to allow for the administration of CCP in an outpatient setting in December 2021, at least for immunocompromised patients or those on immunosuppressive therapy. Outpatient transfusion of CCP and infusion of monoclonal antibody therapies for a highly transmissible infectious disease introduces nuanced challenges related to infection prevention. Drawing on our experiences with the clinical and research use of CCP, we describe the logistical considerations and workflow spanning procurement of qualified products, infrastructure, staffing, transfusion, and associated management of adverse events. The purpose of this description is to facilitate the efforts of others intent on establishing outpatient transfusion programs for CCP and other antibody‐based therapies.
Explaining the unexplained: applying genetic testing after cardiac arrest and sudden death
Behr, Elijah R. , Behr, Elijah Raphael

Mayo Clinic

European Heart Journal | March 25, 2022 | Volume: 43 | Issue: 32 | Pages: 3082-3084

10.1093/eurheartj/ehac172 | PMID 35380654 Get It